At present, tumor immunotherapy mainly refers to programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1) antibodies and chimeric antigen receptor T-cell immunotherapy (CAR-T) for the treatment of refractory or relapsed acute B lymphoblastic leukemia. The gene discussed is CD274; the disease is neoplasm.